BRIEF—Dieter Weinand to chair Anaveon board

Former Bayer Pharma chief executive Dieter Weinand is the new chair of Anaveon’s board of directors.

Martin Murphy, who has served as chair since 2019, has stepped down from the board of the Swiss immuno-oncology company.

Mr Weinand has also held senior roles with Pfizer, Bristol Myers Squibb  and Sanofi during his 30 years in pharma.

Andreas Katopodis, CEO at Anaveon, said: “We are pleased to welcome Dieter to Anaveon’s board. He brings a wealth of strategic and operational experience to Anaveon as we look to advance our lead solid tumor programs through clinical studies and expand our pipeline with novel drug candidates.

“We are greatly indebted to Martin for his contributions and guidance as chair since the founding of the company and wish him every success in the future.”